Kratom advocates learning from CBD, marijuana state-by-state strategy

The American Kratom Association (AKA) should follow the state-by-state strategy used by proponents of medical marijuana and CBD, said Mac Haddow, senior fellow on public policy for the AKA.

The FDA has limited success opposing kratom but uses incomplete information, Haddow says. When the AKA counters with more complete scientific information, it prevails.

In 20 states considering a ban, “we have won in every one of those just by going to the state legislators and presenting the science,” Haddow said.

Kratom is “a consumer product that should be available to consumers like a food or a dietary ingredient,” he said. “Consumers have a right to make informed decisions about using products to maintain their health and well being.”

The AKA does not support kratom vendors who make unsupported health claims for the product.

As it champions kratom at the state level, the AKA noted the success of CBD products. Former FDA Commissioner Dr. Stephen Hahn made news last year when he said that trying to get CBD products off the market was “a fool’s game,” referring to their widespread availability.

Haddow contends that the FDA’s concerns about kratom have been completely refuted. He compared the agency’s opposition to kratom as being similar to its opposition to dietary supplements and vitamins in the 1990s. As long as products are not adulterated - kratom or dietary supplements - they are safe, he says.

Original article: http://bit.ly/kratomcbd